Metabolic Insights

Inflammation to Type 2 Diabetes — The Pathway Mapped | 2026 It happens to a lot of people, and it follows a pattern that's almost too reliable to be random. The morning starts reasonably well — coffee helps, the brain engages, the to-do list feels manageable. Then somewhere around 2 or 3 in the afternoon, something shifts. Not dramatically. Not a collapse. Just a heaviness that settles into the shoulders, a fogginess that makes the screen feel like it's slightly out of focus, a gravitational pull toward the couch that has nothing to do with how much sleep happened the night before. Most people chalk it up to the post-lunch dip , to not sleeping enough, to stress. And sometimes that's accurate. But there's a layer of biology beneath those explanations that doesn't get nearly as much attention in workplace wellness conversations as it deserves — and that layer involves chronic low-grade inflammation , a state of persistent immune activation that research has i...

CRP & Liver Fat — What Employer Wellness Programs Track | 2026 Corporate wellness programs have come a long way from the biometric screening table in the break room — the one where a nurse took your blood pressure, handed you a printout, and advised you to eat more vegetables. That version still exists in a lot of organizations. But alongside it, something considerably more analytically sophisticated has been growing quietly, driven by employer healthcare cost data, advances in population health technology, and a gradually accumulating research literature that connects specific metabolic and inflammatory markers to the kind of long-horizon healthcare costs that self-insured employers and large health plan sponsors care most deeply about. CRP. Liver fat. Insulin resistance proxies. Metabolic syndrome component clustering. These aren't terms that used to appear in workforce wellness conversations. They're appearing now — not always in language that employees see direc...

Inflammation & Health Insurance Risk — What Insurers See | 2026 Most people think about health insurance risk in fairly concrete terms — a diagnosis, a prescription, a procedure that shows up in a medical record. Something documented, labeled, and handed to an underwriter. But there's a quieter category of risk that insurers and actuaries have been paying increasing attention to over the past two decades, one that lives in the gray zone between "officially sick" and "perfectly fine." Chronic low-grade inflammation sits squarely in that gray zone. It doesn't usually produce a diagnosis on its own. It doesn't have a billing code the way a fractured wrist or a documented thyroid condition does. But it shows up in blood markers. It accumulates over years. And the research connecting it to cardiovascular disease, type 2 diabetes, metabolic syndrome, and a range of costly chronic conditions has become extensive enough that the insurance industry — ...

Visceral vs Subcutaneous Fat — Why Fat Location Drives Risk | 2026 Body fat has a geography problem — or rather, most public conversations about fat ignore the fact that geography is almost everything. The number on a scale, the BMI on a chart, the total fat percentage from a body scan: these are blunt instruments. What the research keeps returning to, year after year, is not how much fat a person carries but where that fat lives inside the body. Two people can have nearly identical body weights, nearly identical BMI readings, nearly identical outward appearances — and carry metabolically very different fat profiles . One may store the majority of their fat in subcutaneous depots, tucked just beneath the skin across the hips, thighs, and upper arms. The other may carry a larger proportion deep inside the abdominal cavity, wrapped around internal organs. Same scale number. Quite different biological pictures. Understanding why that distinction matters — mechanistically, not ju...